{"id":"11c-choline","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"}]},"_chembl":{"chemblId":"CHEMBL920","moleculeType":"Small molecule","molecularWeight":"104.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"11C-choline is a radiolabeled tracer where carbon-11 is incorporated into choline, a precursor for phosphatidylcholine synthesis. Rapidly dividing and metabolically active cells, including cancer cells, exhibit increased choline uptake and incorporation into cell membranes. The radioactive carbon-11 allows detection via PET imaging, facilitating localization and characterization of tumors.","oneSentence":"11C-choline is a positron emission tomography (PET) imaging agent that accumulates in tissues with high choline metabolism, enabling visualization of metabolically active lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:56:03.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer imaging and detection"},{"name":"Brain tumor imaging"},{"name":"Lung cancer imaging"}]},"trialDetails":[{"nctId":"NCT03768349","phase":"EARLY_PHASE1","title":"PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-01-03","conditions":"Prostate Cancer","enrollment":250},{"nctId":"NCT06647966","phase":"","title":"Diagnostic Performance of [11C]Choline PET/CT In the Preoperative Assessment of Primary Hyperparathyroidism","status":"NOT_YET_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2025-01","conditions":"Primary Hyperparathyroidism","enrollment":200},{"nctId":"NCT04560725","phase":"NA","title":"PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-10-22","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04608253","phase":"","title":"A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT in Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2015-01-01","conditions":"Primary Hyperparathyroidism, Primary Hyperparathyroidism Due to Adenoma","enrollment":36},{"nctId":"NCT06179706","phase":"","title":"11C-choline PET/CT Based Helical Tomotherapy as Innovative Treratment Approach for Bone Metastases in Prostate Cancer Patients.","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2015-10-27","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT04693169","phase":"NA","title":"[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-01-15","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT06180252","phase":"","title":"PET Study of Acetylcholine Esterase Activity in Alzheimer's Disease","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2004-05-12","conditions":"Alzheimer Disease","enrollment":30},{"nctId":"NCT06170164","phase":"","title":"Radiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2015-10-08","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT06167824","phase":"","title":"Assessment of Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure Without Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2014-06-19","conditions":"Prostate Cancer","enrollment":302},{"nctId":"NCT06168890","phase":"","title":"Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure.","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2014-02-04","conditions":"Prostate Cancer","enrollment":195},{"nctId":"NCT02849171","phase":"NA","title":"Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-07","conditions":"Brain Cancer","enrollment":8},{"nctId":"NCT02815033","phase":"PHASE2","title":"Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide","status":"COMPLETED","sponsor":"The European Uro-Oncology Group","startDate":"2015-07","conditions":"Prostate Cancer Metastatic","enrollment":66},{"nctId":"NCT05087134","phase":"EARLY_PHASE1","title":"Characterizing LAM With 11C-Choline PET/CT","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-11","conditions":"Lymphangioleiomyomatosis","enrollment":50},{"nctId":"NCT03404648","phase":"PHASE3","title":"Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-11-01","conditions":"Prostate Adenocarcinoma","enrollment":19},{"nctId":"NCT02004418","phase":"PHASE1, PHASE2","title":"A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":21},{"nctId":"NCT02397408","phase":"PHASE2","title":"11C- and 18F-Choline PET/MR Imaging for Prostate Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-04-09","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT02519075","phase":"","title":"11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE","status":"COMPLETED","sponsor":"Istituto Clinico Humanitas","startDate":"2015-04","conditions":"Hepatocarcinoma","enrollment":14},{"nctId":"NCT02531672","phase":"","title":"Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography","status":"NO_LONGER_AVAILABLE","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"","conditions":"Prostate Cancer, Recurrent Prostate Cancer","enrollment":""},{"nctId":"NCT02260817","phase":"PHASE3","title":"Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"Global Isotopes, LLC d/b/a Zevacor Molecular","startDate":"2014-10","conditions":"Metastatic Prostate Cancer","enrollment":109},{"nctId":"NCT03451812","phase":"","title":"Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-01-01","conditions":"Prostate Adenocarcinoma","enrollment":120},{"nctId":"NCT00804245","phase":"PHASE1","title":"C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-08","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT01051479","phase":"PHASE1","title":"A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2010-03","conditions":"Esophageal Cancer","enrollment":22},{"nctId":"NCT02462447","phase":"","title":"Carbon-11 Labeled Sarcosine in Prostate Cancer","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2015-06","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT02355054","phase":"","title":"Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study","status":"APPROVED_FOR_MARKETING","sponsor":"Washington University School of Medicine","startDate":"","conditions":"Cancer of the Prostate","enrollment":""},{"nctId":"NCT02852122","phase":"NA","title":"The Role of C-11 Choline PET in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2015-01","conditions":"Latent Cancer Prostate","enrollment":54},{"nctId":"NCT00987376","phase":"PHASE1","title":"Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-11","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT01132599","phase":"PHASE2","title":"Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer","status":"WITHDRAWN","sponsor":"Cancer Research UK","startDate":"2010-05","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT01377220","phase":"PHASE2","title":"Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Commissariat A L'energie Atomique","startDate":"2011-06","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT01221896","phase":"","title":"Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2011-01","conditions":"Hyperparathyroidism","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":281,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["11C-CH","CCH Injection, C11 Choline Injection"],"phase":"phase_3","status":"active","brandName":"11C-choline","genericName":"11C-choline","companyName":"University of Michigan","companyId":"university-of-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"11C-choline is a positron emission tomography (PET) imaging agent that accumulates in tissues with high choline metabolism, enabling visualization of metabolically active lesions. Used for Prostate cancer imaging and detection, Brain tumor imaging, Lung cancer imaging.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}